Pluri Inc.
Biotechnology firm with 3D cell-expansion tech for manufacturing cell-based products.
PLUR | TA
Overview
Corporate Details
- ISIN(s):
- US72942G2030
- LEI:
- Country:
- Israel
- Address:
- Park Building No. 5, 3508409 Haifa
- Website:
- https://pluri-biotech.com/
- Sector:
- Manufacturing
Description
Pluri Inc. is a biotechnology company specializing in proprietary 3D cell-expansion technology. The company develops and operates platforms for the scalable, consistent, and cost-effective manufacturing of cell-based products. Its technology is applied across multiple sectors, including regenerative medicine, cell therapy, food technology, and agriculture technology (AgTech). Pluri aims to create next-generation cell-based products to improve human wellbeing and establishes partnerships to leverage its platform. The company also provides Contract Development and Manufacturing Organization (CDMO) services.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-23 10:01 |
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffe…
|
English | 36.3 KB | ||
| 2024-01-08 16:32 |
FORM 8-K-Pluri Launches Advanced Global Cell Therapy Contract Development and M…
|
English | 109.4 KB | ||
| 2024-01-08 16:32 |
FORM 8-K-Pluri Launches Advanced Global Cell Therapy Contract Development and M…
|
English | 36.3 KB | ||
| 2024-01-08 15:06 |
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufactur…
|
English | 249.0 KB | ||
| 2024-01-08 15:06 |
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufactur…
|
English | 36.3 KB | ||
| 2023-11-14 00:21 |
Form 10Q For the quarterly period ended September 30, 2023
|
English | 1.4 MB | ||
| 2023-11-14 00:21 |
Form 10Q For the quarterly period ended September 30, 2023
|
English | 36.4 KB | ||
| 2023-10-20 01:18 |
Received a letter from Nasdaq approving an extension of an additional 180 calen…
|
English | 144.4 KB | ||
| 2023-10-20 01:18 |
Received a letter from Nasdaq approving an extension of an additional 180 calen…
|
English | 36.2 KB | ||
| 2023-09-13 01:29 |
FORM S-3/A (Amendment No. 1)
|
English | 593.6 KB | ||
| 2023-09-13 01:29 |
FORM S-3/A (Amendment No. 1)
|
English | 36.1 KB | ||
| 2023-09-13 01:17 |
FORM 10-K For the fiscal year ended June 30, 2023
|
English | 3.8 MB | ||
| 2023-09-13 01:17 |
FORM 10-K For the fiscal year ended June 30, 2023
|
English | 36.3 KB | ||
| 2023-08-16 16:01 |
Pluri’s PLX-R18 Increases Blood Cell Counts & Reduces Need for Transfusions in …
|
English | 168.6 KB | ||
| 2023-08-16 16:01 |
Pluri’s PLX-R18 Increases Blood Cell Counts & Reduces Need for Transfusions in …
|
English | 36.2 KB |
Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pluri Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pluri Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
